Choose License Type
The global negative pressure wound therapy market was valued at USD 1,892.1 million in 2018. Increasing costs of health care, aging population, recognition of difficult-to-treat infection threats such as biofilms, and the continued threat of diabetes and obesity worldwide are the key drivers for the growth of global negative pressure wound therapy market. However, varying reimbursement policies regarding the use of NPWT devices in developed regions may hinder the market growth.
NPWT is used to treat acute and chronic wounds and was established over the last 20 years in the U.S. and Europe. The cornerstone of the therapy is the distribution of negative pressure over the whole wound area. The main clinical benefits of NPWT are rapid reduction of wound area by contraction of wound margins, the granulation tissue formation by mechanically induced cell proliferation, convenient wound cleansing due to removal of cell debris and elimination of wound exudates along with the cytotoxic compounds. Some described economic benefits of NPWT are cost savings availed from faster and better healing of wounds, faster wound bed preparation necessary for further surgical wound closure techniques and earlier discharge from the hospital, and quicker recuperation period.
The global negative pressure wound therapy market has been split into product, wound type and end user segments. Among the product types, single use NPWT devices are set to grow at a highest CAGR of 5.2% owing to portability feature, which simplifies ease of use. In the wound type segments surgical and traumatic wounds owned the largest market share of 47.68% in 2018. Surgical site infections (SSI) represent a major concern in overall healthcare, both in developed and developing parts of the world. Despite all efforts, SSI contributes to mortality in 75% of cases.
In 2018, North America held majority market share in negative pressure wound therapy market. Moreover, emerging economies of APAC and MEA region are set to grow at a highest pace, bypassing other regions. Market growth in these regions is fuelled by increasing health awareness, investments made by market players and government initiatives to provide better healthcare facilities. Prominent players operating in the global negative pressure wound therapy market are 3M Company, Smith & Nephew, Lohmann & Rauscher, Mölnlycke Health Care AB, Genadyne, Cardinal Health, ConvaTec and Medela among others.
Key segments of the global negative pressure wound therapy market
Product Overview, 2015-2025 (USD Million)
Wound Type Overview, 2015-2025 (USD Million)
End User Overview, 2015-2025 (USD Million)
Regional Overview, 2015-2025 (USD Million)
Reasons for the study
What does the report include?
Who should buy this report?
Consultants, analysts, researchers, and academicians looking for insights shaping the global negative pressure wound therapy market
The global NPWT devices market is a consolidated market where the top four market players occupy about 50% market share. These players are vigorously targeting each other’s products and undertaking several strategic initiatives in order to capture market share.
The following is a snapshot of strategies undertaken by the market players:
Geographic Expansion - They are entering new regional markets through acquisitions, increased product registrations, tailored portfolio development, post-acute and community reimbursement initiatives and expansion of commercial channels
Strategic Acquisitions - They intend to augment growth by identifying, acquiring and integrating businesses, technologies and products that enhance product portfolio, while diversifying customer base. Competitors also seek strategic alliances, which will allow to pursue new opportunities with greater flexibility and lower capital commitments.
Focused Innovation - They are focused on building product portfolio and innovative pipeline including several new product offerings and line extensions. In addition, they are implementing focused global research and development, and marketing functions so as to develop and commercialize products and solutions well-tailored to the needs of customers and care settings across different geographies.
However, as the players also desire to lower costs and increase efficiency of NPWT, it gives rise to several market movements; for example, healthcare providers increasingly seeking to treat patients in outpatient or community settings; the increasing use of digital technologies to ensure that care is as efficient and effective as possible; the acceptance of ‘good enough’ products in some circumstances; and the sector is increasingly seeing efforts to cooperate across the value chain. As an example, the UK National Health Service (NHS) is automating data exchange between its institutions and suppliers and has mandated all suppliers to provide pricing information through the Global Data Synchronization Network (GDSN) by October 2018 (NHS, Feb 2016).
The National Institutes of Health’s (NIH) Research Portfolio Online Reporting Tool (RePORT) now lists wounds as a category. The Medicare cost estimates for acute and chronic wound treatments ranges from USD 28.1 billion to USD 96.8 billion, with a higher trend towards costs associated with outpatient wound care compared with inpatient.
Global Negative Pressure Wound Therapy Market Segmentation
The global negative pressure wound therapy market has been segmented based on products, wound type and end user. Based on wound type, the market is categorized into surgical and traumatic wounds, ulcers and burns. Surgical and traumatic wounds was the largest segment in 2018 and is expected to retain its dominance through 2025; moreover, ulcers are projected to grow at a highest CAGR of 5.3%. Ulcers have been further split into diabetic foot ulcers, pressure ulcers and venous ulcers, with venous ulcers dominating the negative pressure wound therapy market in 2018 with 42.6% market share.
A vast majority of lower-extremity ulcers are caused by chronic venous insufficiency. In the U.S. and Europe, people >65 years of age are vulnerable to venous ulcers. In the U.S, 10% to 35% of the population suffers from some kind of chronic venous issue, with 4% (>65 age group) of the cases having active ulcers. In the United States and the United Kingdom, venous leg ulcers cost around USD 2.5 billion, and EUR 300 to EUR 600 million, respectively. The annual expenditure to treat a venous ulcer is estimated at USD 10,563. For chronic, non-healing venous ulcers, the treatment expenditure is estimated to be around USD 34,000 or higher. Chronic venous ulcers’ burden on economic productivity by resulting in the loss of 4.6 million work days per year.
Based on estimates originating from independent sources, it is clear that the magnitude of wounds as a healthcare problem is sharply rising. Resources allocated to the education, care, and research of wounds continues to be disproportionately low and deserves strategic attention.
North America was the market leader of negative pressure wound therapy in 2018, occupying over 45% market share, followed by Europe. However, emerging economies are set to grow at the fastest pace in the forecast period. KCI, a 3M company gains 65% of its revenue share from the U.S, whereas Smith & Nephew dominates the European market.
In the United States, 3% of the population >65 years of age have open wounds. By 2020, the US government estimates that the elderly population will be over 55 million, suggesting that chronic wounds will continue to be an increasingly persistent problem in this population. Overall, in the United States 2% of the total population are estimated to be affected by chronic wounds. The impact of chronic wounds is also adverse worldwide. For example, a 2016 report from Wales estimated a 6% prevalence of chronic wounds with a 5.5% cost to the National Health Service (NHS). The Centers for Disease Control and Prevention (CDC) released a study indicating that more than 100 million adults are living with diabetes or prediabetes in the United States. As of 2015, 30.3 million Americans (9.4% of the U.S. population) live with diabetes; besides, 84.1 million have prediabetes, which if left untreated, often leads to type 2 diabetes (T2D) within 5 years.
The global negative pressure wound therapy market was valued at USD 1,892.1 million in 2018. Increasing costs of health care, aging population, recognition of difficult-to-treat infection threats such as biofilms, and the continued threat of diabetes and obesity worldwide are the key drivers for the growth of global negative pressure wound therapy market. However, varying reimbursement policies regarding the use of NPWT devices in developed regions may hinder the market growth.
NPWT is used to treat acute and chronic wounds and was established over the last 20 years in the U.S. and Europe. The cornerstone of the therapy is the distribution of negative pressure over the whole wound area. The main clinical benefits of NPWT are rapid reduction of wound area by contraction of wound margins, the granulation tissue formation by mechanically induced cell proliferation, convenient wound cleansing due to removal of cell debris and elimination of wound exudates along with the cytotoxic compounds. Some described economic benefits of NPWT are cost savings availed from faster and better healing of wounds, faster wound bed preparation necessary for further surgical wound closure techniques and earlier discharge from the hospital, and quicker recuperation period.
The global negative pressure wound therapy market has been split into product, wound type and end user segments. Among the product types, single use NPWT devices are set to grow at a highest CAGR of 5.2% owing to portability feature, which simplifies ease of use. In the wound type segments surgical and traumatic wounds owned the largest market share of 47.68% in 2018. Surgical site infections (SSI) represent a major concern in overall healthcare, both in developed and developing parts of the world. Despite all efforts, SSI contributes to mortality in 75% of cases.
In 2018, North America held majority market share in negative pressure wound therapy market. Moreover, emerging economies of APAC and MEA region are set to grow at a highest pace, bypassing other regions. Market growth in these regions is fuelled by increasing health awareness, investments made by market players and government initiatives to provide better healthcare facilities. Prominent players operating in the global negative pressure wound therapy market are 3M Company, Smith & Nephew, Lohmann & Rauscher, Mölnlycke Health Care AB, Genadyne, Cardinal Health, ConvaTec and Medela among others.
Key segments of the global negative pressure wound therapy market
Product Overview, 2015-2025 (USD Million)
Wound Type Overview, 2015-2025 (USD Million)
End User Overview, 2015-2025 (USD Million)
Regional Overview, 2015-2025 (USD Million)
Reasons for the study
What does the report include?
Who should buy this report?
Consultants, analysts, researchers, and academicians looking for insights shaping the global negative pressure wound therapy market
1. Introduction
1.1. Introduction to the Study
1.2. Market Definition and Scope
1.3. Units, Currency, Conversions and Years Considered
1.4. Key Stakeholders
1.5. Key Questions Answered
2. Research Methodology
2.1. Introduction
2.2. Data Capture Sources
2.2.1. Primary Sources
2.2.2. Secondary Sources
2.3. 3.3 Market Size Estimation
2.4. 3.4 Market Forecast
2.5. 3.5 Data Triangulation
2.6. 3.6 Assumptions and Limitations
3. Market Outlook
3.1. Introduction
3.2. Value Chain Analysis
3.3. Macroeconomic Indicators
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.4.4. Challenges
3.5. Porter’s Five Forces Analysis
3.6. Regulatory Scenario
4. Negative Pressure Wound Therapy Market by Product, 2015-2025 (USD Million)
4.1. Conventional NPWT devices
4.2. Single use NPWT devices
5. Negative Pressure Wound Therapy Market by Wound Type, 2015-2025 (USD Million)
5.1. Surgical and traumatic wounds
5.2. Ulcers
5.2.1. Diabetic foot ulcers
5.2.2. Pressure ulcers
5.2.3. Venous ulcers
5.3. Burns
6. Negative Pressure Wound Therapy Market by End User, 2015-2025 (USD Million)
6.1. Hospitals and clinics
6.2. Home care setting
6.3. Other
7. Negative Pressure Wound Therapy Market by Region 2015-2025 (USD Million)
7.1. North America
7.1.1. US
7.1.2. Canada
7.2. Europe
7.2.1. UK
7.2.2. Germany
7.2.3. France
7.2.4. Rest of Europe
7.3. Asia Pacific
7.3.1. China
7.3.2. Japan
7.3.3. India
7.3.4. Rest of APAC
7.4. Rest of the World
8. Competitive Landscape
8.1. Company Ranking
8.2. Market Share Analysis
8.3. Strategic Initiatives
8.3.1. Mergers & Acquisitions
8.3.2. New Product Launch
8.3.3. Investments
8.3.4. Expansion
8.3.5. Others
9. Company Profiles
9.1. 3M Company
9.1.1. Overview
9.1.2. Products and Services Portfolio
9.1.3. SWOT
9.1.4. Recent Initiatives
9.1.5. Company Financials
9.2. Smith & Nephew plc.
9.3. Mölnlycke Health Care
9.4. ConvaTec Group plc.
9.5. Cardinal Health, Inc.
9.6. DeRoyal Industries
9.7. Lohmann & Rauscher International GmbH & Co. Kg
9.8. Talley Group Ltd.
9.9. Medela
9.10. Genadyne Biotechnologies, Inc.
9.11. Other companies
9.11.1. Applied Tissue Technologies LLC
9.11.2. Worldwide Innovative Healthcare, Inc.
9.11.3. ATMOS MedizinTechnik GmbH & Co. KG
10. Appendix
10.1. Primary Research Approach
10.1.1. Primary Interview Participants
10.1.2. Primary Interview Summary
10.2. Questionnaire
10.3. Related Reports
10.3.1. Published
10.3.2. Upcoming